Publications
Publications
- May 2000
- HBS Case Collection
To Trim or Not to Trim: That Is the Question
By: Srikant M. Datar
Abstract
Should Novartis drop 20% of its global pharmaceutical product brands that account for only 3% of its pharmaceutical revenues?
Keywords
Business Earnings; Cost vs Benefits; Business Strategy; Investment Return; Problems and Challenges; Pharmaceutical Industry
Citation
Datar, Srikant M. "To Trim or Not to Trim: That Is the Question." Harvard Business School Case 100-105, May 2000.